Table 1.
miRNAs (miRs) down-regulating BCL-w level. miRs and cell lines involved in experiments that directly evidenced the binding of particular miR to 3’-UTR of BCL-w transcript are included.
| In vitro | |||
|---|---|---|---|
| miR | Cell line | Cell type | Reference |
| let-7a-3p | U251 and A172 | Glioblastoma multiforme | 107 |
| miR-15a | A549 | Non-small cell lung cancer | 162 |
| FaDu | Hypopharyngeal squamous cell carcinoma | 163 | |
| miR-15b | SNU475 | Hepatocellular carcinoma | 164 |
| miR-16 | SCC-25 | Oral squamous cell carcinoma | 165 |
| miR-29a | HEC-1B | Human endometrial carcinoma | 166 |
| miR-29b | HEK293 | Human embryonic kidney epithelial cells | 76 |
| U251 and U87MG | Glioblastoma multiforme | 141 | |
| miR-29b-1-5p | - | Mouse cardiomyocytes | 50 |
| miR-29c | A549 | Non-small cell lung cancer | 167 |
| miR-34a-5p | HEK293 | Human embryonic kidney epithelial cells | 168 |
| miR-92a | H9c2 | Rat cardiomyocytes | 169 |
| miR-93-5p | U251 | Glioblastoma multiforme | 152 |
| H460 | Lung cancer | ||
| miR-107 | A549/Taxol | Paclitaxel-resistant non-small cell lung cancer | 110 |
| HT-22 | Immortalized hippocampal neuron cells | 170 | |
| miR-122 | Hep3B and HepG2 | Hepatocellular carcinoma | 171 |
| Mahlavu | Hepatocellular carcinoma (gefitinib-resistant) | 172 | |
| HeLa | Cervical cancer | 173 | |
| Huh7, Hep3B and HepG2 | Hepatocellular carcinoma | ||
| H460 | Lung cancer | ||
| HepG2 | Hepatocellular carcinoma | 174 | |
| - | Pterygium epithelial cells | 88 | |
| miR-125a-5p | PLC/PRF/5 | Hepatocellular carcinoma | 175 |
| miR-125b | - | Rat hippocampal and cervical neurons | 176 |
| SMMC7721 | Hepatocellular carcinoma | 177 | |
| miR-126-5p | SiHa and HeLa | Cervical cancer | 178 |
| miR-129-2-3p | MDA-MB-231 | Breast cancer | 179 |
| miR-133b | T24 | Bladder cancer | 115 |
| U2OS and MG63 | Osteosarcoma | 180 | |
| H2009 | Non-small cell lung cancer | 181 | |
| miR-146-5p | SKOV3 | Ovarian cancer | 182 |
| miR-150 | SKpac | Paclitaxel-resistant ovarian cancer | 183 |
| oxi-miR-184 | H9c2 | Rat cardiomyocytes | 184 a |
| miR-195 | BEL7402 | Hepatocellular carcinoma | 130 |
| BEL7402/5-FU | Hepatocellular carcinoma (5-FU-resistant) | ||
| HT29 and LOVO | Colon cancer | 101 | |
| HCM | Human cardiomyocytes | 51 | |
| miR-203 | HEK293 | Human embryonic kidney epithelial cells | 114 |
| HCT116 | Colon cancer | 48 | |
| T24 and 5637 | Bladder cancer | 116 | |
| SGC-7901 | Gastric cancer | 185 | |
| miR-204 | HTM1073 and HTM681 | Human trabecular meshwork cells | 186 |
| miR-205 | WPE1-NA22 and WPE1-NB26 | Prostate cancer | 126 |
| H460 | Lung cancer | 103 b | |
| MDA-MB-231 | Breast cancer | ||
| miR-206 | MCF-7 and TY7D | Breast cancer | 108 b |
| miR-214 | HeLa | Cervical cancer | 120 |
| HEK293 | Human embryonic kidney epithelial cells | 187 c | |
| miR-336 | SKOV3 and ES2 | Ovarian cancer | 140 |
| SGC-7901 | Gastric cancer | 143 | |
| A549 and H1299 | Non-small cell lung cancer | 109 | |
| 786-O and CaKi-1 | Clear cell renal carcinoma | 119 | |
| A2780 | Ovarian cancer | 127 b | |
| A2780/DDP | Ovarian cancer (cisplatin-resistant) | ||
| A498 and 786-O | Renal cell carcinoma | 49 b | |
| miR-340-5p | U251 and U87 | Glioblastoma multiforme | 188 |
| miR-378 | SKM-1 | Acute myeloid leukemia | 189 |
| miR-422a | U2OS and MG63 | Osteosarcoma | 123 |
| mmu-miR-466h | CHO | Mammalian Chinese hamster ovary | 190 |
| miR-497 | N2A | Mouse neuroblastoma | 74 |
| MCF-7 | Breast cancer | 191 | |
| miR-509-3p | HEK293T | Human embryonic kidney epithelial cells | 192 |
| miR-630 | JHU-029 | Head and neck squamous cell carcinoma | 133 |
| SW480 and HT29 | Colorectal cancer | 45 | |
| In vivo | |||
|---|---|---|---|
| miR | Cell type | In vivo experimental model | Reference |
| miR-15a | Neuronal cells | miR-15a/16-1null mice | 75 |
| miR-16 | Oral squamous cell carcinoma | BALB/c nude mice | 166 |
| miR-92a | Rat cardiomyocytes | Sprague–Dawley rats | 169 |
| miR-107 | Paclitaxel-resistant non-small cell lung cancer | Nude mice | 110 |
| miR-122 | Gefitinib-resistant hepatocellular carcinoma | BALB/c nude mice | 174 |
| miR-205 | Lung cancer and breast cancer | BALB/c nude mice | 103 b |
| miR-336 | Gastric cancer | BALB/c nude mice | 143 |
| Cisplatin-resistant ovarian cancer | BALB/c nude mice | 127 b | |
| Renal cell carcinoma | Nude mice | 49 | |
| miR-378 | Acute myeloid leukemia | NOD/SCID mice | 189 |
| miR-497 | Neuronal cells | C57/B6 mice | 74 |
aROS-mediated oxidative modification of miR-184 (oxi-miR-184) is indispensable for recognition of BCL-w mRNA.
b5p form of miR was used.
c3p form of miR was used.